Agents that elevate cellular cAM P are know n to inhibit the activation of phospholipase D (PLD). W e investigated w hether PLD can be phosphorylated by cAM P-dependent protein kinase (PKA) and PKA-m ediated phosphorylation affects the interaction betw een PLD and RhoA, a m em brane regulator of PLD. PLD1, but not PLD2 w as found to be phosphorylated in vivo by the treatm ent of dibutyryl cA M P (dbcA M P) and in vitro by PKA. PKA inhibitor (KT5720) abolished the dbcAM P-induced phosphorylation of PLD1, but dibutyryl cGMP (dbcGMP) failed to phosphorylate PLD1. The association betw een PLD1 and Val14RhoA in an im m unoprecipitation assay w as abolished by both dbcAM P and dbcG M P. M oreover, RhoA but not PLD1 w as dissociated from the m em brane to the cytosolic fraction in dbcAM P-treated cells. These results suggest that both PLD1 and RhoA are phosphorylated by PKA and the interaction betw een PLD1 and RhoA is inhibited by the phosphorylation of RhoA rather than by the phosphorylation of PLD1.
Introduction
Phospholipase D (PLD) catalyzes the hydrolysis of phosphatidylcholine to generate free choline and phosphatidic acid (PA). PA can be further metabolized by PA phosphohydrolase to form diacylglycerol and by phospholipase A2 to form lysophosphatidic acid. Moreover, PA and its metabolites act as second messengers in the regulation of secretion, mitogenesis, and cytoskeletal reorganization (Exton, 1999; Liscovitch et al., 2000) PLD is tightly regulated by a variety of hormones, growth factors, cytokines, and other agonists (Singer et al., 1997; Frohman et al., 1999) . Two types of PLD have been cloned, PLD1 (~120 kDa) and PLD2 (~105 kDa), which differ both in activation mechanism and subcellular localization (Hammond et al., 1995; Colley et al., 1997) . PLD1 is constitutively inactive and is activated by ADP-ribosylation factor (ARF), RhoA, and protein kinase C (PKC) (Hammond et al., 1995) . In contrast, PLD2 is constitutively active but insensitive to ARF and RhoA (Colley et al., 1997) . Previous studies have demonstrated that the effector region (switch I) of RhoA interacts with the C-terminus of human PLD1 (Bae et al., 1998; Yamazaki et al., 1999; Cai and Exton, 2001 ). Moreover, in vivo studies have shown that PLD can be activated by the direct binding of RhoA (Du et al., 2000; Xie et al., 2002) .
The intracellular accumulation of cAMP leads to functional inhibition in various cells. Increased cAMP in neutrophils lead to the subsequent inhibition of PLD, suggesting that cross-talk is present between the PLD and the cAMP-dependent pathways (Agwu et al., 1991; Tyagi et al., 1991) . Our previous study showed that PLD activation was inhibited by cAMPdependent protein kinase (PKA) in a cell-free system of neutrophils . A component of the plasma membrane has been identified as the target of inhibition by PKA, and the dissociation of the phosphorylated active form of RhoA from the plasma membrane may be involved in the downregulation of PLD activity . However, no prior evidence of the direct phosphorPhosphorylation of phospholipase D1 and the m odulation of its interaction with RhoA by cAMP-dependent protein kinase ylation of PLD by PKA in vivo and in vitro has been presented. Moreover, direct involvement of the phosphorylations of RhoA and/or PLD in the inhibition of their association is not clearly understood although RhoA phosphorylation by PKA was shown to enhance or inhibit the association between RhoA and its binding proteins, such as Rho GDP dissociation inhibitor (RhoGDI) and Rho kinase (Lang et al., 1996; Dong et al., 1998; Forget et al., 2002; Ellerbroek et al., 2003; Qiao et al., 2003) .
We report here that PLD1 is a substrate of PKA, and that interaction between PLD1 and RhoA is inhibited by RhoA phosphorylation rather than PLD phosphorylation.
M aterials and M ethods Reagents
Dibutyryl cAMP (dbcAMP), dibutyryl cGMP (dbcGMP), protein A-agarose, and the catalytic subunit of PKA (cPKA) were purchased from Sigma (St. Louis, MO); [γ- 32 P]ATP (3,000 Ci/mmol) and [γ-32 P]Pi (3,000 Ci/mmol) from NEN Life Science Products (Boston, MA); Dulbecco's modified Eagle's medium (DMEM) and geneticin (G418) from Gibco-BRL (Grand Island, NY); KT5720 and KT5823 from Calbiochem (La Jolla, CA); anti-Myc antibody from Santa Cruz Biotechnology (Santa Cruz, CA); antibody directed against phospho-(Ser/Thr) PKA substrate from Cell Signaling Technology; the enhanced chemiluminescence (ECL) kit from Amersham Bioscience (Beverly, MA); and FuGENE6 transfection reagent from Roche Applied Science (Manheim, Germany). Antibodies against PLD1 and PLD2 were generated as previously described .
Cell culture and transfection U87 human glioma cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin at 37 o C in a humidified atmosphere containing 5% CO2. pcDNA3.1 containing cDNA for PLD1 or PLD2 were used as expression vectors (Min et al., 2001) . U87 cells were transfected either with the empty vector as a control, or with the PLD-expression vector using LipofectAMINE (Gibco-BRL), following the procedure recommended by the manufacturer. Transfected cells were subsequently grown in selection medium containing 500 µg/ml G418. After 3 weeks, antibiotic-resistant clones were isolated and expanded for further analysis under selected conditions. Cells over-expressing PLD1 (U87/PLD1) and PLD2 (U87/PLD2) were co-expressed with the Myc epitope-tagged constitutively active form of RhoA (Val14RhoA). Briefly, cells (2×10 6 ) in 60 mm culture dish were incubated with FuGENE6 transfection reagent (20 µl) and empty vector or pcDNA3.1 containing the cDNA of Val14RhoA plasmid (4 µg) for 24 h. Cells (2×10 7 ) were treated with or without 300 µM of dbcAMP or dbcGMP for 10 min at 37 o C, washed once with cold phosphate buffered saline (PBS), and resuspended in cold lysis buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1% Triton X-100, 1% deoxycholate, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride). The samples were rotated for 1 h at 4 o C and cell lysates were separated from insoluble material by centrifugation at 13,000 g for 5 min at 4 o C. The samples were precleared using protein A-agarose for 1 h at 4 o C and incubated with anti-PLD antibodies for 1 h at 25 o C. The immune complex obtained was then transferred to 40 µl of 1:1 slurry of protein A-agarose and mixed for 1 h. The beads were pelleted and washed six times with PBS containing 1% Triton X-100. The immunoprecipitated protein complex was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Membranes were blocked for 1 h at 25 o C with a blocking buffer (25 mM Tris-HCl, 0.15 M NaCl, and 0.2% Tween 20), incubated with primary antibodies (1:1,000 in dilution) overnight at 4 o C, washed, and incubated for 1 h with secondary antibodies (1:5,000 in dilution) conjugated to horseradish peroxidase. Signals were detected by chemiluminescence.
Im m unoprecipitation and W estern blot analysis

P incorporation into PLD
The phosphorylation of PLD was determined from the amount of [ 32 P]ATP incorporated into the enzyme after immunoprecipitation with specific PLD antibodies. Cells (5×10 6 cells/ml) were prelabeled with 0.2 mCi/ml [ 32 P]orthophosphate for 90 min and incubated with or without 300 µM of dbcAMP or dbcGMP for 10 min at 37 o C. Phosphorylation of cell extracts with cPKA in vitro was carried out for 30 min at 30 o C in a 100 µl final volume of phosphorylation buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, protease inhibitor mixture, 100 U cPKA, 0.1 mM cold ATP, and 2 µCi [ 32 P]ATP). Cell lysates were immunoprecipitated using PLD antibodies. Samples were subjected to SDS-PAGE and followed by autoradiography of dried gel.
Preparation of m em branes and cytosolic fraction dbcAMP-treated or -untreated cells were centrifuged and resuspended at 2×10 7 cells/ml in ice-cold rela-xation buffer (50 mM Hepes, pH 7.4, 100 mM KCl, 5 mM NaCl, 1 mM MgCl2, 0.5 mM EGTA, and protease inhibitor mixtures). Cell suspensions were sonicated for 20 s and centrifuged for 8 min at 700 g. The supernatants were ultracentrifuged at 100,000 rpm for 45 min in a Beckman TL-100 ultracentrifuge using a TLA-100.4 rotor. Membrane pellets were washed once and resuspended in cold relaxation buffer.
R esults
Phosphorylation of PLD1 by PKA A possible direct phosphorylation of PLD by PKA was examined in vivo or in vitro. U87/PLD1 and U87/PLD2 cells were established by stably transfecting genes for PLD isozymes into U87 cells and were treated with a cAMP-increasing agent, dbcAMP ( Figure 1A ). The rate of cell proliferation was found not to be significantly different between U87/PLD1 or U87/PLD2 cells and control U87 cells (data not shown). This finding suggests that these stable transfectants may be a suitable model for studying interactions between PLD and its binding proteins, including RhoA. Total cell proteins were obtained from detergent-treated lysates, immunoprecipitated with anti-PLD antibodies, separated by SDS-PAGE, and immunoblotted with the anti-phospho-(Ser/Thr) PKA substrate antibody, which allows detection of typical R-X-X-T/S or R-R-X-T/S consensus sequences for PKA (Schmitt and Stork, 2002) . As shown in Figure 1B , dbcAMP induced a marked increase in the phosphorylation of PLD1, but not of PLD2. The phosphorylation of PLD was dramatically increased after 10 min treatment with dbcAMP and this condition was used for further experiments (data not shown).
To determine the effect of dbcAMP on PLD1 phosphorylation by PKA and the specificity of detecting phosphorylated PLD1 with anti-phospho-(Ser/Thr) PKA substrate antibody for PKA-mediated phosphorylation, the effect of a PKA inhibitor was carried out by pretreating cells with the PKA inhibitor, KT5720. The results showed inhibition of PLD1 phosphorylation evidenced by the reduced amount of PLD1 proteins were overexpressed using pcDNA3.1 containing plasmid PLD1 (PLD1) or PLD2 (PLD2) in U87 cells. Cells were transfected with empty vector as a control (pcDNA). Cell lysates (75 µg) were immunoblotted with antibodies against PLD1 (αPLD1) or PLD2 (αPLD2) as described in "Materials and Methods". (B) After cells were treated with (+cAMP) or without (-cAMP) 300 µ M dbcAMP for 10 min at 37 o C, cell lysates (1 mg/ml) were immunoprecipitated using PLD antibodies (2 µ g) and blotted with anti-phospho-(Ser/Thr) PKA substrate antibody. Markers indicate molecular weight. Results are representative of three or four experiments. blotted with anti-phospho-(Ser/Thr) PKA substrate antibody. Whereas, dbcAMP-induced phosphorylation was insensitive to KT5823, an inhibitor of cGMPdependent protein kinase (PKG) and to bisindolylmaleimide I, an inhibitor of PKC (Figure 2A ). To assess PKA's ability to phosphorylate PLD in vitro, cPKA plus ATP was added to cell extracts from U87/ PLD1. As shown in Figure 2B , PKA clearly induced the phosphorylation of immunoprecipitated PLD1. We next examined the effect of cAMP or cGMP on 32 P incorporation into PLD, while monitoring total PLD1 proteins immunoprecipitated with anti-PLD1 antibody in parallel by Western blotting (Figure 3) . As expected, a phosphorylated band co-localized with the immunodetected band of PLD1. However, the cGMP analogue, dbcGMP had little effect on the phosphorylation of PLD1. Taken together, these results demonstrate that elevated intracellular levels of cAMP phosphorylate PLD1 by activating PKA.
Effect of phosphorylation on the interaction betw een PLD1 and RhoA
Binding of the active form of RhoA to PLD was studied by co-immuoprecipitating PLD1 with immobilized RhoA. As shown in Figure 4 , the co-transfection of U87/PLD1 cells with Myc epitope-tagged Val14-RhoA followed by immunoprecipitation with an antiMyc antibody revealed the co-precipitation of PLD1. However, PLD2 was not detected in the co-immunoprecipitates from Val14RhoA-transfected U87/PLD2 cells (data not shown). This result demonstrates a specific association between PLD1 and the active form of RhoA. To determine whether intracellular cAMP levels regulate the association between PLD1 and the active form of RhoA, RhoA was immunoprecipitated from cells treated with or without dbcAMP and the amount of co-precipitated PLD1 was measured. RhoA was reported to be phosphorylated at Ser188 by both PKA and PKG (Lang et al., 1996; Kwak and Uhlinger, 2000; Sauzeau et al., 2000; Sawada et al., 2001) . dbcAMP or dbcGMP induced a marked increase in the phosphorylation of band co-localized with the immunodetected band of Val14-RhoA ( Figure 4B ). The level of PLD1 in Myc immunoprecipitates was markedly reduced in dbcAMP-treated cells in comparison with those in the untreated cells ( Figure 4C ). The addition of cPKA plus ATP also blocked the association between PLD1 and Val14RhoA in cell extracts ( Figure 4D ). These results suggest that the dissociation of the PLD1-RhoA complex occurs by the PKA-mediated phosphorylation of PLD1 and/or RhoA. Interestingly, dbcGMP treatment also induced dissociation between PLD1 and RhoA ( Figure 4C ). Moreover, dbcAMP-induced dissociation was abrogated by the PKA inhibitor, KT5720, whereas dbcGMP- induced dissociation was unaffected by this inhibitor ( Figure 4C ). Since PLD1 is phosphorylated by only cAMP, as observed in the present study, but RhoA is phosphorylated by both cAMP and cGMP, these results suggest that RhoA phosphorylation, rather than PLD1 phosphorylation, inhibits the association between PLD1 and RhoA.
Effect of phosphorylation on the localization of PLD1
Most PLD enzymes are membrane-associated proteins, although cytosolic PLD has been reported in certain cells (Siddiqi et al., 1995; Singer et al., 1997) and the membrane-bound active form of RhoA was extractable by PKA-mediated phosphorylation (Lang et al., 1996; Kwak and Uhlinger, 2000; Forget et al., 2002) . We examined whether cAMP-induced phosphorylation could affect the association of PLD with the membrane. PLD1 and Val14RhoA were detected mainly in the membrane fraction of untreated U87/ PLD1 cells. As shown in Figure 5 , a large amount of Val14RhoA was detected in the cytosolic fraction after dbcAMP treatment. This observation concurs with previous studies on the dissociation of phosphorylated RhoA from membrane. However, phosphorylated PLD1 was not detected in cytosolic fraction. This result suggests that PLD1 phosphorylated by PKA is not dissociated from membrane although its regulatory factor, RhoA can be easily extracted by PKA-mediated phosphorylation.
D iscussion
The target of phosphorylation in the PKA-mediated inhibition of PLD was shown to be the membrane fraction of neutrophils where the enzyme itself and RhoA were located . Recent studies indicate that RhoA is phosphorylated by PKA (Lang et al., 1996; Kwak and Uhlinger, 2000; Ellerbroek et al., 2003) . In this study, we investigated whether PLD can be phosphorylated by PKA both in vivo and in vitro. The PLD1 and PLD2 proteins share 50% homology, and PLD2 does not encode a PLD1-like loop region (Colley et al., 1997; Frohman et al., 1999) . However, there are several potential PKA phosphorylation sites common to PLD1 and PLD2. Our studies using anti-phospho-(Ser/Thr) PKA substrate antibody or 32 P incorporation show that PLD1 but not PLD2 is phosphorylated by PKA. Moreover, these effects were abrogated by PKA inhibitor but were not affected by inhibitors of PKG or PKC, indicating that these effects are specific for PKA. In a broader sense, the functional consequence of PLD1 phosphorylation remains to be determined.
Exton et al. suggested that RhoA might activate PLD by direct interaction, since RhoA can activate PLD in vitro (Bae et al., 1998) . Although the action of RhoA on PLD1 in vivo has been proposed to take place through indirect pathways (Schmidt et al., 1999 ), Frohman's group suggested that direct stimulation of PLD1 in vivo by RhoA is critical for significant PLD1 activation (Du et al., 2000) . Our studies also revealed that PLD1 associates with the active form of RhoA in vivo. Val14RhoA was shown to suppress basal PLD2 activity in vivo (Xie et al., 2002) but our results indicate that PLD2 cannot bind Val14RhoA. Thus, it is possible that the active form of RhoA may affect other regulatory factor(s) rather than PLD2 itself, since PLD2 activation is independent of RhoA.
The detailed molecular mechanism of the downregulation of PLD by PKA is yet to be clarified. Earlier study suggested that increased intracellular concentrations of cAMP might affect the interaction between the enzyme and its regulators through the phosphorylation of RhoA or the PLD enzyme by PKA . Here both cAMP-increasing agent and cGMP-increasing agent inhibited the association between PLD1 and Val14RhoA, although the possible physiological role of PKG in PLD signaling is unknown. This result indicates that RhoA phosphorylation by cAMP and cGMP may affect binding of RhoA to PLD1, since PKA and PKG phosphorylate serine188 on RhoA (Lang et al., 1996; Sauzeau et al., 2000; Sawada et al., 2001; Ellerbroek et al., 2003) . Moreover, consistent with our findings, PKA-mediated phosphorylation decreased the binding of RhoA to another downstream effector molecule, Rho (Dong et al., 1998) . In contrast, the phosphorylation of GTP-bound RhoA by PKA was found to enhance the stabilization of RhoA-RhoGDI (Lang et al., 1996; Ellerbroek et al., 2003; Qiao et al., 2003) . Taken together, the PKA-mediated phosphorylation of RhoA may terminate RhoA signaling by enhancing its binding to inhibitory protein, RhoGDI, and reducing its binding to its effector molecules, including PLD1. Direct binding and activation of PLD1 by RhoA has been shown to strictly depend on the residue in the switch I region (Bae et al., 1998) . Thus, it is possible that the PKA-mediated phosphorylation of Ser188 on RhoA affects a residue responsible for stabilizing the association between RhoA and PLD1. There is another possibility, namely that charge change in RhoA protein caused by the addition of negatively charged Ser188 affects the interaction between PLD and RhoA, since the binding of PLD to RhoA has been shown to involve electrostatic interactions with acidic residues in RhoA (Cai and Exton, 2001) . A possibility of RhoA-RhoGDI complex formation promoted by RhoA phosphorylation remains and may interfere with the association between RhoA and PLD1.
PLD1 is localized mainly in the perinuclear membrane, whereas PLD2 is localized in plasma membrane (Colley et al., 1997) , and it is known that phosphorylation controls the cellular locations of various proteins. In the present study, treatment of U87/ PLD1 cells with dbcAMP did not affect the localization of PLD1. Our earlier observations showed no change in the level of RhoA in plasma membranes treated with PKA plus ATP, but the addition of cytosol or RhoGDI significantly increased the dissociation of phosphorylated RhoA from a PKA-treated plasma membrane . In this study, the PLD1 was found in the membrane fraction of dbcAMP-treated cells, whereas membrane-associated RhoA was extractable by dbcAMP. These results suggest that PKA-mediated phosphorylation does not affect the association between PLD1 and the membrane, but that it enhances the dissociation of RhoA from the membrane by promoting its binding with a cytosolic factor. These findings provide further support for our observation that PKA-mediated phosphorylation reduces the interaction between PLD and the active membrane-bound form of RhoA.
Agonist-induced phosphorylation of PLD itself is accompanied by increase in PLD activity, which appears to be mediated by PKC or tyrosine kinase (Exton, 1999; Frohman et al., 1999) . Chadhdi et al. has shown that endogenous and expressed PLD1 and PLD2 in RBL-2H3 mast cells are activated by PKA but PLD2 appears to be minimally regulated by PKA (Chahdi et al., 2002) . Receptor-stimulated PLD activity but not phorbol ester-stimulated PLD activity was inhibited by PKA . However, cAMP did not affect unstimulated and phorbol ester-stimulated PLD activities in U87/PLD1 or U87/PLD2 cells (data not shown). In addition, Val14RhoA overexpression alone did not augment the PLD activity of U87/PLD1 cells and cGMP also had no effect on formyl-Met-Leu-Phe-stimulated PLD activity in human neutrophil and the activity in U87/PLD1 cells (unpublished data). Inhibition or down-regulation of PKC does not affect the pervanadate-induced PLD activation in Rat2 cells (Kim et al., 2003) . Such effects may be due to differential activation and regulation of PLD by different agonists or involvement of other regulatory factors in the activation of PLD in the cells. The effect of phosphorylation by PKA on the activation of PLD1 is now under investigation.
The present study shows that PLD1 is the substrate for PKA, and PKA-mediated phosphorylation inhibits the interaction between PLD1 and its regulatory factor. Further work is needed to identify residue(s) of PLD phosphorylated by PKA and effect of PLD phosphorylation on the association between itself and other regulatory factors or binding proteins.
